Galcanezumab in chronic migraine

This study evaluated galcanezumab's effectiveness for preventing chronic migraines. Galcanezumab is a humanized monoclonal antibody targeting calcitonin gene-related peptide. It was tested in a phase 3, randomized, double-blind, placebo-controlled study. The study involved patients aged 18 to 65 years with chronic migraines. Participants were randomly assigned to receive either placebo or galcanezumab injections. The injections were given monthly, with two different doses: 120 mg and 240 mg. During the 3-month treatment phase, researchers measured monthly migraine headache days. The average number of monthly migraine headache days at the start was 19.4. Galcanezumab showed a mean reduction of 4.8 days for the 120 mg dose. The 240 mg dose had a reduction of 4.6 days. Both doses were more effective than placebo. Galcanezumab was deemed efficacious, safe, and well tolerated for chronic migraine prevention. Clinical relevance: This study confirms that galcanezumab effectively reduces migraine frequency in patients.